Literature DB >> 18650471

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group.

Thomas Burmeister, Stefan Schwartz, Claus R Bartram, Nicola Gökbuget, Dieter Hoelzer, Eckhard Thiel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18650471     DOI： 10.1182/blood-2008-04-149286

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  42 in total

Review 1.  Philadelphia-positive acute lymphoblastic leukemia: current treatment options.

Authors:  Theresa Liu-Dumlao; Hagop Kantarjian; Deborah A Thomas; Susan O'Brien; Farhad Ravandi
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.

Authors:  Katsumichi Fujimaki; Yukako Hattori; Hideaki Nakajima
Journal:  Int J Hematol       Date:  2017-11-29       Impact factor: 2.490

Review 3.  Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.

Authors:  Philippe Rousselot; André Delannoy
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

Review 4.  Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.

Authors:  Aaron Ronson; Ariella Tvito; Jacob M Rowe
Journal:  Curr Treat Options Oncol       Date:  2017-03

5.  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.

Authors:  Mark B Geyer; Meier Hsu; Sean M Devlin; Martin S Tallman; Dan Douer; Jae H Park
Journal:  Blood       Date:  2017-01-25       Impact factor: 22.113

Review 6.  Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Authors:  Iman Abou Dalle; Elias Jabbour; Nicholas J Short; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

7.  Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.

Authors:  S Couban; L Savoie; Y Abou Mourad; B Leber; M Minden; R Turner; V Palada; N Shehata; A Christofides; S Lachance
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

8.  Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

Authors:  Ohad Benjamini; Theresa Liu Dumlao; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Stefan Faderl; Jeffrey Jorgensen; Rajyalakshmi Luthra; Rebecca Garris; Deborah Thomas; Partow Kebriaei; Richard Champlin; Elias Jabbour; Jan Burger; Jorge Cortes; Farhad Ravandi
Journal:  Am J Hematol       Date:  2014-03       Impact factor: 10.047

9.  mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Authors:  Thanh-Trang T Vo; J Scott Lee; Duc Nguyen; Brandon Lui; William Pandori; Andrew Khaw; Sharmila Mallya; Mengrou Lu; Markus Müschen; Marina Konopleva; David A Fruman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

10.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Authors:  Sabina Chiaretti; Antonella Vitale; Gianni Cazzaniga; Sonia Maria Orlando; Daniela Silvestri; Paola Fazi; Maria Grazia Valsecchi; Loredana Elia; Anna Maria Testi; Francesca Mancini; Valentino Conter; Geertruy te Kronnie; Felicetto Ferrara; Francesco Di Raimondo; Alessandra Tedeschi; Giuseppe Fioritoni; Francesco Fabbiano; Giovanna Meloni; Giorgina Specchia; Giovanni Pizzolo; Franco Mandelli; Anna Guarini; Giuseppe Basso; Andrea Biondi; Robin Foà
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.